Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Tecfidera(®): an approach for repurposing.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
CNS myelin wrapping is driven by actin disassembly.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Neuroprotective effect of masitinib in rats with postischemic stroke.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Prevention and treatment of MS: studying the effects of vitamin D.
Treatment of neuromyelitis optica.
Laquinimod in multiple sclerosis.
Disease-modifying treatments for progressive multiple sclerosis.

Pages